These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2876301)

  • 1. Adjuvant chemotherapy in early breast cancer.
    Raemaekers JM; Beex LV; Smals AG; Benraad TJ; Kloppenborg PW
    Lancet; 1986 Oct; 2(8511):861. PubMed ID: 2876301
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant chemotherapy in breast cancer.
    Bonadonna G; Rossi A; Tancini G; Valagussa P
    Lancet; 1983 May; 1(8334):1157. PubMed ID: 6133169
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?
    Pritchard KI
    J Clin Oncol; 2002 Dec; 20(24):4611-4. PubMed ID: 12488402
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanism of action of adjuvant chemotherapy in early breast cancer.
    Valagussa P; Bonadonna G
    Lancet; 1986 Nov; 2(8514):1035-6. PubMed ID: 2877194
    [No Abstract]   [Full Text] [Related]  

  • 5. [CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer].
    Gottwald G; Szakolczai I
    Orv Hetil; 1983 Jan; 124(2):79-84. PubMed ID: 6687491
    [No Abstract]   [Full Text] [Related]  

  • 6. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
    Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
    J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
    Samur M; Bozcuk HS
    J Clin Oncol; 2003 Jun; 21(12):2444; author reply 2445-7. PubMed ID: 12805349
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
    Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
    J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial considerations in the use of adjuvant chemotherapy.
    Irvin RJ; Kuhn JG
    Cancer Treat Res; 1992; 60():207-22. PubMed ID: 1355987
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy.
    Osborne CK; Coltman CA
    CA Cancer J Clin; 1986; 36(1):59-60. PubMed ID: 3080209
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant chemotherapy in young women with breast cancer.
    Rodríguez-Lescure A
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():39-41. PubMed ID: 20711669
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant therapy for breast cancer.
    Flippin TA; Langston HD; Prather JL; Scott DI
    J Ark Med Soc; 1987 May; 83(12):483-4. PubMed ID: 2956244
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant chemotherapy in breast cancer: back to the future.
    Colleoni M; Goldhirsch A
    Onkologie; 2003 Apr; 26(2):111-2. PubMed ID: 12771517
    [No Abstract]   [Full Text] [Related]  

  • 17. [Adjuvant chemo-hormonal therapy of breast cancer. New results on mortality].
    Kaufmann M; Kubli F; Caffier H; Jonat W; Maass H
    Dtsch Med Wochenschr; 1985 Jun; 110(25):1009-10. PubMed ID: 3839181
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant tamoxifen in postmenopausal stage II breast cancer five years on.
    Mikl J; Aiginger P; Czerwenka K; Kubista E; Salzer H; Sevelda P; Spona J; Staffen A; Zielinski CC
    Lancet; 1990 Mar; 335(8688):541. PubMed ID: 1968551
    [No Abstract]   [Full Text] [Related]  

  • 19. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
    Hartman AR; Fleming GF; Dillon JJ
    Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating the relapsed patient.
    Chlebowski RT
    Cancer Treat Res; 1992; 60():239-53. PubMed ID: 1355989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.